Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

RECLAIM STUDY: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or Overweight

NCT06987513 is registered in ClinicalTrials.gov with Altimmune, Inc. as lead sponsor.

NCT NCT06987513
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06987513 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
RECLAIM STUDY: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or Overweight
Lead sponsor
Altimmune, Inc.
Phase
Phase 2
Overall status
Completed
Start date
May 15, 2025
Completion date
July 30, 2026
Enrollment
100 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

alcohol use disorder (aud)